NE3107 (Bezisterim) Early Parkinson's Trial

NE3107 (Bezisterim) for Early Parkinson's Disease (NCT06757010)

Trial Overview

| Field | Value |
|-------|-------|
| NCT Number | NCT06757010 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | BioVie Inc. |
| Intervention | NE3107 (Bezisterim) |
| Mechanism | TNF-alpha inhibitor, anti-inflammatory |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
| Indication | Early Parkinson's disease |
| Enrollment | 60 subjects (estimated) |
| Treatment Duration | 12 weeks |
| Dosage | 20 mg NE3107 BID (40 mg daily) vs. placebo |

Introduction and Clinical Significance

NE3107 (Bezisterim) for Early Parkinson's Disease (NCT06757010)

Trial Overview

| Field | Value |
|-------|-------|
| NCT Number | NCT06757010 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | BioVie Inc. |
| Intervention | NE3107 (Bezisterim) |
| Mechanism | TNF-alpha inhibitor, anti-inflammatory |
| Route | Oral |
| Study Design | Randomized, double-blind, placebo-controlled |
| Indication | Early Parkinson's disease |
| Enrollment | 60 subjects (estimated) |
| Treatment Duration | 12 weeks |
| Dosage | 20 mg NE3107 BID (40 mg daily) vs. placebo |

Introduction and Clinical Significance

Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the hallmark motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability. Additionally, non-motor symptoms such as cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life[@caldi2021].

Despite decades of research, current treatments remain primarily symptomatic, focusing on dopamine replacement therapy with levodopa and dopamine agonists. While these interventions provide substantial benefit, they do not halt or slow disease progression. The development of disease-modifying therapies remains an urgent unmet need[@tansey2018].

Neuroinflammation has emerged as a critical driver of PD pathogenesis. Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine that plays a central role in the neuroinflammatory processes contributing to dopaminergic neuron degeneration. Elevated TNF-α levels have been documented in the brains, cerebrospinal fluid, and peripheral blood of PD patients, correlating with disease severity and progression[@bauer2020][@chen2023].

Drug Profile: NE3107 (Bezisterim)

Mechanism of Action

NE3107 (Bezisterim) is a novel oral TNF-alpha inhibitor developed by BioVie Inc. Unlike monoclonal antibody TNF inhibitors (such as infliximab, adalimumab, etanercept) that target TNF-α systemically, NE3107 is designed as a small molecule that can penetrate the blood-brain barrier and target neuroinflammation directly in the central nervous system[@mcguire2019].

The molecular mechanism involves:

Pharmacological Properties

NE3107 has demonstrated favorable pharmacological properties in preclinical studies:

• Oral bioavailability: Designed for convenient daily oral administration
• BBB penetration: Small molecule structure allows access to CNS targets
• Selective TNF inhibition: Targets TNF-α specifically without broad immunosuppression
• Anti-inflammatory efficacy: Demonstrated reduction in pro-inflammatory cytokine production

Comparison with Other TNF Inhibitors

The therapeutic landscape for TNF inhibition in neurodegeneration includes several approaches[@bokhari2023]:

| Drug | Type | BBB Penetration | Use in PD |
|------|------|-----------------|-----------|
| NE3107 | Small molecule | Yes | Under investigation |
| Infliximab | Monoclonal antibody | Limited | Experimental |
| Etanercept | Recombinant protein | Limited | Experimental |
| Adalimumab | Monoclonal antibody | Limited | Experimental |

The key advantage of NE3107 is its small molecule design, which enables direct targeting of neuroinflammation in the brain rather than merely peripheral TNF-α.

Preclinical Evidence in Parkinson's Disease

Neuroinflammatory Mechanisms in PD

TNF-α contributes to Parkinson's disease pathogenesis through multiple mechanisms[@kaur2022]:

Evidence from Preclinical Models

Studies support TNF-α inhibition as a therapeutic strategy for PD[@chen2023]:

• Dopaminergic neuron protection: TNF-α blockade preserves tyrosine hydroxylase-positive neurons in the substantia nigra
• Motor function improvement: Animal models show improved performance in rotarod and cylinder tests
• Inflammation reduction: Decreased microglial activation and reduced pro-inflammatory cytokine expression
• α-synuclein mitigation: Reduced α-synuclein phosphorylation and aggregation

Mechanism Validation

The neuroprotective effects of TNF-α inhibition are mediated through[@bauer2020]:

Study Design

• Design: Randomized, double-blind, placebo-controlled, parallel-group
• Population: Early Parkinson's Disease (idiopathic PD within 18 months of diagnosis)
• Treatment-naïve: No prior levodopa or dopamine agonists

Eligibility Criteria

Inclusion

• Age 45-80 years
• Idiopathic Parkinson's Disease diagnosed within 18 months
• Treatment-naïve (no prior levodopa, carbidopa, or similar dopaminergic drugs)

Exclusion

• Secondary parkinsonism
• Prior dopaminergic therapy
• Significant cognitive impairment

Endpoints

Primary Endpoint

• Change from baseline in MDS-UPDRS Part III at 12 weeks

Secondary Endpoints

• Change from baseline in MDS-UPDRS Parts I and II at 12 weeks
• Percent of subjects with improvement in Clinical Global Impression

Trial Sites

Scientific Rationale

TNF-α in Parkinson's Disease Pathogenesis

TNF-α plays a central role in PD pathogenesis through multiple pathways[@tansey2018]:

Clinical Evidence in PD Patients

Studies have demonstrated elevated TNF-α in PD patients:

• Elevated CSF TNF-α: Increased levels in cerebrospinal fluid correlating with disease severity
• Serum biomarkers: Elevated peripheral TNF-α associated with motor progression
• PET imaging: Increased TSPO binding indicating microglial activation
• Post-mortem studies: Elevated TNF-α in substantia nigra of PD brains

Why Oral Small Molecule?

The choice of an oral small molecule TNF inhibitor addresses key limitations of existing biologic therapies:

• BBB penetration: Small molecules can reach CNS targets
• Oral administration: Convenience over intravenous biologics
• Peripheral immunosuppression avoidance: Local CNS effect without systemic immunosuppression
• Infection risk: Lower infection risk compared to systemic immunosuppression

Rationale for Early Parkinson's Disease

The trial focuses on early-stage Parkinson's disease for several important reasons:

Potential Benefits and Risks

Expected Benefits

Based on preclinical data, NE3107 may provide:

Risk Considerations

Potential risks include:

• Gastrointestinal effects: Nausea, diarrhea
• Headache: Common in early clinical trials
• Peripheral immunosuppression: Though designed for CNS, systemic effects possible
• Drug interactions: Potential interactions with other medications
• Unknown long-term safety: Limited long-term data in PD population

Cross-References and Related Content

For more detailed information, see related pages:

• [TNF Signaling in Neurodegeneration](/mechanisms/tnf-signaling-neurodegeneration) — Detailed mechanism of TNF-α in neurodegeneration
• [Neuroinflammation in Parkinson's](/mechanisms/neuroinflammation-parkinsons) — Background on neuroinflammatory processes
• [Microglial Activation in Parkinson's](/mechanisms/microglia-neuroinflammation) — Role of microglia in PD pathogenesis
• [Parkinson's Disease](/diseases/parkinsons-disease) — Disease overview
• [Anti-inflammatory Therapies for Neurodegeneration](/therapeutics/anti-inflammatory-therapy-neurodegeneration) — Overview of anti-inflammatory approaches
• [TNF Inhibitors in Neurodegeneration](/therapeutics/infliximab-neurodegeneration) — TNF inhibitor therapy overview
• [Dapansutrile for Parkinson's](/clinical-trials/dapansutrile-pd-nct07157735) — Another NLRP3 inflammasome inhibitor in trials
• [BiIB122 (Luma) LRRK2 Inhibitor](/clinical-trials/biib122-luma-lrrk2-inhibitor-pd) — LRRK2 targeting approach
• [AMX0035 (Centaur) for PD](/clinical-trials/amx0035-centaur) — Another neuroprotective approach

Comparison with Other Neuroprotective Approaches

Several disease-modifying approaches are in development for PD:

| Approach | Target | Stage | Mechanism |
|----------|--------|-------|-----------|
| NE3107 | TNF-α | Phase 2 | Anti-inflammatory, neuroprotective |
| Dapansutrile | NLRP3 | Phase 2 | Inflammasome inhibition |
| BiIB122 | LRRK2 | Phase 2 | Kinase inhibition |
| AMX0035 | TDP-43/mitochondrial | Phase 2/3 | Dual mechanism |
| Inosine | Urate | Phase 3 | Antioxidant |

Each approach targets different pathological mechanisms, and multiple successful therapies could potentially be combined for additive benefit.

Conclusion

The Phase 2 clinical trial of NE3107 (Bezisterim) for early Parkinson's disease (NCT06757010) represents an important step toward developing disease-modifying therapies for PD. By targeting TNF-α, a central mechanism of neuroinflammation, NE3107 offers a novel approach that addresses the underlying pathophysiology of PD rather than merely alleviating symptoms.

The scientific foundation supporting this trial includes:

Successful development of NE3107 would not only validate TNF-α inhibition as an effective PD therapy but also establish this approach as a viable strategy for other neurodegenerative disorders characterized by neuroinflammation.

References